Physician profile
David A Paslin
NPI 1477650901
$4,027.07
in general payments reported to CMS, 2019-2025
25 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $665 · 2021: $788 · 2022: $486 · 2023: $441 · 2024: $297 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.55 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $668.00 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $581.38 | 2019-2024 | |
| Lilly USA, LLC | $371.62 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $345.22 | 2019-2020 | |
| Leo Pharma INC. | $320.74 | 2020-2025 | Adbry, Spevigo, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $229.88 | 2019-2025 | Libtayo, Dupixent |
| Janssen Scientific Affairs, LLC | $206.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.57 | 2022-2024 | Spevigo |
| Dermira, INC. | $181.63 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $177.68 | 2019-2023 | Absorica Ld, Winlevi |
| Genzyme Corporation | $161.35 | 2019-2022 | |
| Genentech USA, INC. | $72.18 | 2019 | |
| Galderma Laboratories, L.P. | $70.42 | 2019 | |
| Pfizer INC. | $68.17 | 2019-2025 | |
| Biofrontera INC. | $64.38 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $53.23 | 2025 | Vtama |
| Organogenesis INC. | $48.85 | 2023-2024 | Puraply, Apligraf |
| Dermavant Sciences, INC. | $44.96 | 2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $41.47 | 2019-2021 | |
| Merz North America, INC. | $26.21 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.89 | 2022 | |
| Mayne Pharma Commercial LLC | $23.85 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.70 | 2021 | |
| Celgene Corporation | $19.79 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $17.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Paslin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.